Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' DEFICIT (Details Narrative)

v3.22.1
STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)
 3 Months Ended
Feb. 26, 2021
Jun. 15, 2020
Dec. 29, 2017
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Sep. 29, 2021
Feb. 09, 2021
Dec. 31, 2020
Class Of Warrant Or Right [Line Items]                  
Convertible notes principal amount       $ 20,341,000   $ 18,007,000      
Common stock, issued       49,311,864 49,311,864        
Share-based compensation       $ 5,000 $ 181,000        
Vesting period remaining for recognition of unrecognized compensation expense       1 year 1 month 6 days          
Research and development       $ 466,000 1,809,000        
Kainos Medicine, Inc [Member]                  
Class Of Warrant Or Right [Line Items]                  
Payments to research and development expense $ 500,000                
Common stock shares issued for consideration 324,675                
Addition to equity for common stock $ 500,000                
Research and development       0 1,000,000.0        
2021 Stock Incentive Option Plan [Member]                  
Class Of Warrant Or Right [Line Items]                  
Common stock, issued             4,000,000    
2011 Stock Incentive Option Plan [Member]                  
Class Of Warrant Or Right [Line Items]                  
Total unrecognized compensation expense       16,000          
2011 Stock Incentive Option Plan [Member] | Stock Options [Member]                  
Class Of Warrant Or Right [Line Items]                  
Share-based compensation       $ 5,000 $ 182,000        
Convertible Promissory Note [Member]                  
Class Of Warrant Or Right [Line Items]                  
Number outstanding       1,250,000   1,250,000      
Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]                  
Class Of Warrant Or Right [Line Items]                  
Convertible notes principal amount   $ 3,150,000              
Debt instrument exercise price   $ 2.05              
Extended maturity date   Jun. 15, 2023              
Percentage of monthly payments interest rate   12.00%           2.00% 11.00%
Expected life (in years)   5 years              
Number outstanding   1,250,000              
GPB Debt Holdings II, LLC [Member] | Senior Secured Convertible Promissory Note [Member]                  
Class Of Warrant Or Right [Line Items]                  
Debt face amount percentage     240,764            
Debt instrument exercise price     $ 10.80            
Initial warrants exercisable period after issuance     5 years            
GPB Debt Holdings II, LLC [Member] | Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member]                  
Class Of Warrant Or Right [Line Items]                  
Convertible notes principal amount     $ 13,000,000            
Convertible notes aggregate purchase price     $ 12,500,000            
Original issue discount percentage     4.00%            
Debt instrument, repaid date       2018-02